$8m loss sparks Football Australia 'right sizing'
Close to five years since A-Leagues split from FA to run their own competition under the umbrella of the Australian Professional Leagues, the picture is increasingly bleak for both of the sport's major bodies.
A-League club distributions were down to just $530,000 this season, while FA's deficit came on revenues of $124 million.
The 22nd Annual General Meeting (AGM) of Football Australia Limited was held at (3:00pm AEST) on Friday, 23 May 2025 at Football Australia's offices, in Sydney and via videoconference.The AGM coincided with the release of the Football Australia 2024 Annual Report.📰 More… pic.twitter.com/lmM7ibFBas
— Football Australia (@FootballAUS) May 23, 2025
FA were reluctant to divulge the breakdown of their sizeable loss, but a big part is understood to be $12 million owed to them by the APL.
The APL are also believed to have grievances with FA over their financial arrangements but regardless of who owes who what, Garriock said the two factions enjoy a relationship that has never been more positive.
Garriock's comments came after an AGM in Sydney on Friday - that was closed off to the media - which signalled the re-election of Anter Isaac as chair.
"The relationship with APL and Football Australia as it stands at the moment is the best it's been and we need to build on that," Garriock said.
"By us having a strong A-League is only going to benefit our national teams and the investment in our national teams are at a record high ... In terms of us cutting any national teams, absolutely not.
"We're investing heavily, and we continue to invest in our grassroots.
"We need to focus internally, and that's what we're doing.
"Anter spoke about the revenues and how we can make up that money. I think it's about right sizing the business, and that's what I'm here to do."
Isaac said FA was "rekindling" its relationship with the APL but would not "write off any amounts" of monies owed.
"We have zero concerns about the commercial relationships that we have with APL," he said.
"Our relationship with APL is probably characterised in two ways. There's the commercial relationship and then there's the strategic relationship - on both counts, it's very strong."
The elephant in the room remains whether Garriock has an appetite to take on the role of chief executive permanently.
The former Matilda diplomatically tiptoed around the issue of replacing James Johnson, who quit earlier this month and was announced as having taken a role in Canada overnight.
"I've been given a mandate from the board in this interim period, and I'm fully focused on the interim period, and I haven't thought beyond that," she said.
Garriock said the next Matildas coach would be announced in June with Joe Montemurro seemingly sewn up as the man to lead the side into next year's Women's Asian Cup.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Coty Announces Filing of Annual Report on Form 10-K for the Fiscal Year Ended June 30, 2025
NEW YORK, August 21, 2025--(BUSINESS WIRE)--Regulatory News: Coty Inc. (NYSE: COTY; PARIS: COTY) today announced that on August 21, 2025, the Company filed its annual report on Form 10-K for the fiscal year ended June 30, 2025 with the U.S. Securities and Exchange Commission (the "SEC"). The annual report is available on the SEC's website at: About Coty in Paris in 1904, Coty is one of the world's largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care. Coty serves consumers around the world, selling prestige and mass market products in over 120 countries and territories. Coty and our brands empower people to express themselves freely, creating their own visions of beauty; and we are committed to protecting the planet. Learn more at or on LinkedIn and Instagram. View source version on Contacts For more information:Investor RelationsOlga Levinzon, +1 212 389-7733olga_levinzon@ MediaAntonia Werther, +31 621 394495antonia_werther@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Wire
4 hours ago
- Business Wire
BayCom Corp Increases Quarterly Cash Dividend
WALNUT CREEK, Calif.--(BUSINESS WIRE)--BayCom Corp (NASDAQ: BCML) ('BayCom' or the 'Company'), the parent company of United Business Bank, today announced that its Board of Directors declared a quarterly cash dividend of $0.25 per share on the Company's common stock, which represents a 25% increase (from $0.20 per share) in the Company's quarterly dividend. The dividend is payable on October 9, 2025 to shareholders of record as of the close of business on September 11, 2025. About BayCom Corp The Company, through its wholly owned operating subsidiary, United Business Bank, offers a full range of loans, including SBA, CalCAP, FSA and USDA guaranteed loans, and deposit products and services to businesses and their affiliates in California, Nevada, Washington, New Mexico and Colorado. The Bank is an Equal Housing Lender and a member of FDIC. The Company's common stock is traded on the NASDAQ under the symbol 'BCML.' For more information, go to Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to the Company's financial condition, results of operations, plans, objectives, future performance or business, including information regarding the ability of BayCom to pay dividends in the future. You should not place undue reliance on these statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may be materially different from any future results or performance suggested by the forward-looking statements in this release. Factors that might cause such differences include, but are not limited to, the Company's financial condition and results of operations, general economic conditions, as well as those within the Company's industry, and numerous other factors identified in BayCom's Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and other documents filed with or furnished to the Securities and Exchange Commission. Such forward-looking statements speak only as of the date of this release. The Company expressly disclaims any obligation to update or revise any forward-looking statements made herein to reflect any changes in the Company's expectations of results or any change in events.
Yahoo
14 hours ago
- Yahoo
Lexeo Therapeutics' Friedreich Ataxia Gene Therapy Receives FDA Breakthrough Therapy Designation
Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 7, the US FDA granted Breakthrough Therapy designation to Lexeo Therapeutics for its investigational drug, LX2006, which is a gene therapy for Friedreich ataxia/FA. The designation was based on interim clinical data from two ongoing trials—the Lexeo-sponsored SUNRISE-FA Phase 1/2 trial and the Weill Cornell Medicine investigator-initiated Phase 1A trial. To date, 17 participants have been treated across both studies. The interim data showed that LX2006 was associated with clinically meaningful improvements in cardiac biomarkers and cardiac and neurologic functional measures. A close-up of a hand holding a vial of biopharmaceutical drugs ready to be administered. In all participants with available cardiac biopsies, an increase in frataxin expression was observed three months after treatment. This is particularly significant as cardiomyopathy is the leading cause of death in FA, with cardiac dysfunction accounting for the cause of death in approximately two-thirds of patients. The company expects to begin a registrational study by early 2026 and is currently enrolling patients in a natural history study, CLARITY-FA, to serve as an external control arm. Lexeo Therapeutics Inc. (NASDAQ:LXEO) is a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases with high unmet need in the US. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.